Home/Filings/4/0000950170-23-026500
4//SEC Filing

Bodenrader Mark 4

Accession 0000950170-23-026500

CIK 0001805387other

Filed

Jun 4, 8:00 PM ET

Accepted

Jun 5, 8:07 PM ET

Size

9.2 KB

Accession

0000950170-23-026500

Insider Transaction Report

Form 4
Period: 2023-06-01
Bodenrader Mark
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2023-06-01+4,7337,417 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-06-014,73314,199 total
    Common Stock (4,733 underlying)
  • Sale

    Common Stock

    2023-06-02$32.95/sh1,895$62,4405,522 total
Footnotes (4)
  • [F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
  • [F2]Includes 2,684 shares previously acquired under the Issuer's Employee Stock Purchase Plan.
  • [F3]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and intended to qualify under Rule 10b5-1.
  • [F4]On June 1, 2022, the Reporting Person was granted 18,932 RSUs under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. 25% of the RSUs vest on each of the first, second, third and fourth anniversary of June 1, 2022, subject to the Reporting Person's continued service relationship with the Issuer through each such date.

Documents

1 file

Issuer

Cerevel Therapeutics Holdings, Inc.

CIK 0001805387

Entity typeother

Related Parties

1
  • filerCIK 0001830371

Filing Metadata

Form type
4
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 8:07 PM ET
Size
9.2 KB